Moreover, 10-year OS and DFS were 67.8% and 85.6%, respectively, in patients with HPVDNA+/p16+ TSCC/BOTSCC and 11.5% and 50.9%, respectively, in patients with HPVDNA−/p16− cancer. This evidence concerns the gene CDKN2A and cancer.